Contact Us marketing@medicilon.com
Medicilon Logo
|
search icon search icon 中 contact icon menu icon
Medicilon Logo
|
search icon close search icon 中 contact icon menu icon
ABOUT
Company Profile
Corporate Culture
Management Team
Company History
Message from the CEO
Honors and Awards
Over 20 years of experience in R&D
Learn more
01 Drug Discovery
Chemistry Research
Biology Research
Early Pharmacokinetics
02 Pharmaceutical Research
Intermediates
Active Pharmaceutical Ingredients
Pharmaceutical preparation
Analytical Method Development and Quality Control
CMC Filings
Analytical Testing Center
03 Preclinical Research
Pharmacology & Pharmacodynamics
Drug Safety Evaluation
DMPK
Bioanalysis
IND Filings
01 One-stop Integrated Services
Liposome Drug Development Service Platform
Drug Discovery Platform
Pharmaceutical Research Platform
Preclinical Research Services
Botanical Drug Preclinical R&D Technology Platform
02 Innovative Drug Services
ADC R&D Service Platform
PROTAC R&D Service Platform
mRNA Vaccine Bioanalysis Platform
Non-clinical Research for Cellular Immunotherapies
Nucleic Acid Drug R&D Platform
Peptide Drug Conjugate (PDC) R&D Service Platform
Antibody R&D Service
03 Key Technical Services for Drug R&D
Cytokine and Biomarker Detection Platform
Metabolite Identification (MetID) Service Platform
Drug Forming Research Platform
Flow Cytometry Technology Platform
SEND Format Conversion Platform
Flow Sorting Platform
NanoString nCounter Detection Platform
Routes of Drug Administration Platform
04 Drug Efficacy Evaluation for Common Diseases
IO Pharmacodynamic Model Evaluation Platform
Pharmacodynamic Evaluation Model Platform for Inflammatory and Immune Diseases
Rodent Cerebrovascular Disease Drug Efficacy Evaluation System
05 Advanced Preparation R&D
Inhalation drug R&D platform
Ophthalmic drug R&D platform
Skin Topical Preparation R&D Platform
06 Targeted Drugs R&D Services
STAT3-targeted Drugs R&D Service
GLP-1 New Drug R&D Service
KRAS-targeted Drugs R&D Service
CAREERS
Talent Development
Recruitment
Talent Development
Talent Development
Recruitment
Recruitment
News
Medicilon Events
Featured Stories
Market Events
Videos
A.C.E.
2024-07-22Medicilon Events
The Shanghai Overseas Returned Scholars Association invites the Dutch PhD delegation to visit Medicilon, exploring paths for innovative development together
On July 4th, the Shanghai Overseas Returned Scholars Association invited the Dutch PhD delegation to visit the Chuansha campus of Shanghai Medicilon Inc. (Medicilon) and held discussions with Medicilon's Founder and CEO, Chunlin Chen, among others.
Learn more
2024-07-22Medicilon Events
5th consecutive win! Medicilon once again made the list of "Top 20 Chinese R&D CRO Enterprises in 2024"
Medicilon stood out among hundreds of pharmaceutical enterprises and was honored with the "Top 20 Chinese R&D CRO Enterprises in 2024" award.
Learn more
INVESTORS
Stock Information
Investment Contact
Medicilon 688202
RMB

As of Beijing time The data is from a third-party organization and is only for reference.

For actual information, please refer to：www.eastmoney.com

CLIENT CENTER
Intellectual Property Protection
Clients Testimonials
Downloads
Partnerships
Medicilon Support
Newsletters
U.S.

Address: 470 Wildwood Ave, Woburn, MA 01801 (America)

Tel: +1(626)986-9880

UK

Address: Allia Future Business Centre Kings Hedges Road Cambridge CB4 2HY, UK

Tel: 0044 7790 816 954

Email: marketing@medicilon.com

China

Address: No.585 Chuanda Road, Pudong New Area, Shanghai (Headquarters)

Postcode: 201299

Tel: +86 (21) 5859-1500 (main line)

Fax: +86 (21) 5859-6369

Close

© 2023 Shanghai Medicilon Inc. All rights reserved Shanghai ICP No.10216606-3

Shanghai Public Network Security File No. 31011502018888 | Website Map

© 2023 Shanghai Medicilon Inc. All rights reserved Shanghai ICP No.10216606-3
Shanghai Public Network Security File No. 31011502018888|Website Map
关闭
中
Message
Contact Us
Close Button
Back To Top
Online Message×
Click switch
Close Button
Customer Center
Customer Center
Case Studies Clients Testimonials Downloads Partnerships Intellectual Property Protection Newsletters
HomeClient CenterMedicilon SupportIND 100
IND 100 Publications
Jul 27,2023
Medicilon Assisted - The IND application of BIOT-001, the first self-developed new drug of Biotime Biotechnology, was approved by the FDA
The IND application for the BIOT-001 project targeting the S1P1 target declared by Biotime Biotechnology obtained the US FDA's clinical implied license. Medicilon provided preclinical R&D services from target to IND declaration for the R&D of BIOT-001, and made every effort to complete the project with high quality and efficiency.
See More
Medicilon Assisted - The IND application of BIOT-001, the first self-developed new drug of Biotime Biotechnology, was approved by the FDA
Jul 27,2023
Medicilon Assist - The IND application for the first new drug NB002 of Neologics Bioscience was approved by the FDA for clinical application
Recently, Neologics Bioscience announced that its research and development pipeline NB002 for the treatment of solid tumors has successfully passed the review of the US FDA and agreed to conduct phase I clinical trials. Medicilon provided preclinical research services such as safety evaluation and pharmacokinetics.
See More
Medicilon Assist - The IND application for the first new drug NB002 of Neologics Bioscience was approved by the FDA for clinical application
Jun 26,2023
Medicilon congratulates MindRank's GLP-1RA small molecule oral drug for successfully administering the first subject in clinical phase I
MindRank's GLP-1RA small molecule oral drug has been successfully administered to the first subject in clinical phase I. Medicilon as a strategic partner of MindRank, provided MDR-001 with API process development and preparation R&D services to help speed up its research and development.
See More
Medicilon congratulates MindRank's GLP-1RA small molecule oral drug for successfully administering the first subject in clinical phase I
Jun 21,2023
Medicilon Assists Toll Biotech's TollB-001 tablets, a new class 1.1 drug, to officially approve for clinical trials by the FDA
Recently, the IND application of TollB-001 Tablets, a class 1.1 new drug for rheumatoid arthritis by Toll Biotech, has been officially approved by the FDA. Medicilon provided pharmaceutical research services, including raw materials and preparation, for TollB-001 tablets, which accelerated the research process.
See More
Medicilon Assists Toll Biotech's TollB-001 tablets, a new class 1.1 drug, to officially approve for clinical trials by the FDA
Jun 14,2023
Congratulations on the positive phase I clinical results of Raymon Pharma's first Chinese eye drops for the treatment of wAMD
Recently, Raymon Pharma announced that the clinical trial of self-developed RA1115-B1 eye drops for the treatment of neovascular (wet) age-related macular degeneration (wAMD) was launched in China. Medicilon provided pharmaceutical research services such as raw material drug production, raw material drug process development, and preparation prescription process development to accelerate the R&D process.
See More
Congratulations on the positive phase I clinical results of Raymon Pharma's first Chinese eye drops for the treatment of wAMD
Jun 05,2023
Congratulations to Gluetacs Therapeutics' new drug clinical research application for GT919, the first molecular glue degradation agent pipeline, approved by the FDA
Recently, Gluetacs Therapeutics (Gluetacs)'s first class 1 new drug, GT919 Capsules, a molecular glue degradation agent pipeline, was approved by the US Food and Drug Administration (FDA) to enter clinical trials. Medicilon's one-stop preclinical R&D service platform empowering new drug research and development.
See More
Congratulations to Gluetacs Therapeutics' new drug clinical research application for GT919, the first molecular glue degradation agent pipeline, approved by the FDA
Mar 14,2023
Medicilon Assists Xuanzhu Biopharmaceutical's KM501, a First Double-antibody ADC Drug that Completely Knocks Out Fucose, has been Approved for Clinical Trials
Recently, Xuanzhu Biopharmaceutical (Xuanzhu) and its wholly-owned subsidiary Beijing Xuanzhu Bio, obtained clinical trial approval for the double-antibody ADC drug KM501 (No.: 2023LP00278). Medicilon as a partner of Xuanzhu, provided KM501 with GLP-compliant preclinical research services based on the Medicilon Antibody Development Service Platform, including pharmacokinetic studies and safety evaluation.
See More
Medicilon Assists Xuanzhu Biopharmaceutical's KM501, a First Double-antibody ADC Drug that Completely Knocks Out Fucose, has been Approved for Clinical Trials
Mar 03,2023
Medicilon assists Carephar first potassium-ion-competitive acid blocker "Carenoprazan Tablets" approved for sales in China
The Class 1 new drug Carenoprazan Hydrochloride Tablets, for the treatment of duodenal ulcer and reflux esophagitis, independently developed by Jiangsu Carephar was officially approved for sales in market. Medicilon has provided research and development from compound design to preclinical candidate compounds, as well as most of the in vitro H+K+-ATPase testing and other services and the Carenoprazan has been successfully approved.
See More
Medicilon assists Carephar first potassium-ion-competitive acid blocker "Carenoprazan Tablets" approved for sales in China
Feb 24,2023
Medicilon Assists CGeneTech's Oral Hypoglycemic DPP-4 Inhibitor, New Drug Application (NDA) Accepted
CGeneTech submitted the DPP-4 inhibitor, for the treatment of type 2 diabetes, to the NMPA for approval. Medicilon, as a partner of CGeneTech, provided comprehensive preclinical research services in compliance with GLP regulations, including pharmacodynamic research, pharmacokinetic research and safety evaluation, as well as Phase I clinical bioanalysis to facilitate its efficient and high-quality R&D.
See More
Medicilon Assists CGeneTech's Oral Hypoglycemic DPP-4 Inhibitor, New Drug Application (NDA) Accepted
Feb 17,2023
Medicilon Helps iMBioRay's CAR-raNK Cell Therapy Approved Clinical Trial
Recently, IBR854 Cell Injection of iMBioRay (Hangzhou) Biomedical Co., Ltd. (iMBioRay) obtained the permission of the NMPA for clinical trials. Shanghai Medicilon Inc. (Medicilon), as a partner of IBR854 Cell Injection, provides efficient, high-quality and comprehensive preclinical research services (including pharmacokinetic studies and safety evaluation) in compliance with GLP regulations. The IBR854 Cell Injection is successfully approved at the end.
See More
Medicilon Helps iMBioRay's CAR-raNK Cell Therapy Approved Clinical Trial
Stock Code
688202

Global

Address: 470 Wildwood Ave, Woburn, MA 01801 (America)

Tel: +1(626)986-9880(U.S.)

Address: Allia Future Business Centre Kings Hedges Road Cambridge CB4 2HY, UK

Tel: 0044 7790 816 954 (Europe)

Email: marketing@medicilon.com

  

Address: 5th Floor, 62, Banpodae-ro 4-gil, Seocho-gu, Seoul, 06719 South Korea

Tel: +82 70-8269-5849

China

Address: No.585 Chuanda Road, Pudong New Area, Shanghai (Headquarters)

Postcode: 201299

Tel: +86 (21) 5859-1500 (main line)

Fax: +86 (21) 5859-6369

Facebook icon
Twitter icon
Linkedin icon
Youtube icon
© 2023 Shanghai Medicilon Inc. All rights reserved All Rights Reserved Privacy Policy
Website Map
-->